Name: 글로벌 시장 동향
SKU: PH4314
Availability: InStock

보고서 요약(국문)

시장 개요
전 세계 경구 점막 투여 약물 시장은 2022년 150억 520만 달러에 달했으며, 2030년까지 244억 4,140만 달러에 이르러 높은 성장세를 보일 것으로 예상됩니다. 경구 점막 투여 약물 시장은 예측 기간(2023~2030년) 동안 연평균 6.4%의 성장률을 기록할 것으로 전망됩니다.
전 세계적으로 만성 또는 비전염성 질환이 증가하고 있으며, 이는 전체 사망 원인의 73%를 차지합니다. 인도에서는 비전염성 질환이 장애 조정 수명 손실의 44%와 전체 사망 원인의 53%를 차지합니다. 전 세계 인구의 6분의 1 이상이 거주하는 인도는 상당한 사회경제적 발전을 경험하고 있으며, 만성 비전염성 질환의 증가 추세는 경구 점막 투여 약물 시장의 성장을 촉진하고 있습니다.

코로나19 팬데믹으로 인해 특히 지역사회 환경에서 말기 환자 및 완화 치료를 위한 대체 약물 투여 경로에 대한 수요가 급증했습니다. 점막 투여 경로는 비강, 구강, 설하 및 직장 투여를 포함합니다. 이러한 경로는 비침습적인 전신 약물 전달 방식으로, 환자 본인이 직접 투여하거나 가족 간병인이 투여할 수 있다는 장점이 있습니다. 자가면역 질환 발생 증가, 기술 발전, 경구 약물 시장 개발 등의 요인이 전 세계 경구 점막 투여 약물 시장 성장을 촉진하고 있습니다.

시장 동향
자가면역 질환 및 암 발생률 증가가 시장 성장을 견인
예를 들어, 미국 암 협회는 매년 미국 내 신규 암 발생 건수와 사망자 수를 추산하고, 인구 기반 암 발생률 및 결과에 대한 최신 데이터를 집계합니다. 2022년 미국에서는 1,918,030건의 새로운 암 발병 사례와 609,360건의 암 사망이 발생할 것으로 예상되었으며, 이 중 폐암으로 인한 사망자는 하루 약 350명에 달했습니다. 폐암은 미국에서 가장 흔한 암 원인입니다. 이처럼 암 발병률 증가는 시장 성장을 촉진합니다.
점막 투여의 기술적 과제
점막 투여는 비침습적이며 환자 스스로 또는 숙련된 의료진에 의해 투여할 수 있기 때문에 경구 및 주사 투여 방식보다 선호됩니다. 점막 투여에 적합한 약물을 찾기 위해서는 점막 약물 흡수 메커니즘을 이해하는 것이 매우 중요합니다. 비강, 구강 및 직장 점막은 각각 특정한 형태학적 및 생리학적 특성을 가지고 있지만, 몇 가지 공통점도 있습니다.

COVID-19 영향 분석
공급망 차질, 정부의 봉쇄 조치, 인력 부족, 제조 활동 제한 등으로 인해 COVID-19 팬데믹은 경구 점막 투여 약물 시장에 단기적으로 부정적인 영향을 미쳤습니다. 그러나 경구 점막 투여 약물 제조업체들은 빠른 작용 발현과 함께 초회 통과 대사를 줄이는 특성을 제공함으로써 코로나바이러스 발생 상황을 기회로 삼고 있습니다. 이러한 특성 덕분에 경구 점막 투여 약물은 증상 완화를 신속하게 제공하는 완화 치료 및 임종 치료에 유용하게 사용될 수 있습니다. 특히 일부 환자의 건강 상태가 급격히 악화되는 상황에서 COVID-19 팬데믹 기간 동안 이러한 약물의 필요성이 더욱 커졌습니다.
러시아-우크라이나 분쟁 분석
러시아-우크라이나 분쟁은 해당 지역의 주요 시장 참여 기업의 존재 및 발생률이 낮아 전 세계 경구 점막 투여 약물 시장에 미치는 영향이 미미할 것으로 예상됩니다. 그러나 원자재 수출입의 영향은 예측 기간 동안 전 세계 경구 점막 투여 약물 시장에 큰 영향을 미치지 않을 것으로 예상됩니다.
인공지능 영향 분석
인공지능(AI)은 제약 산업을 비롯한 여러 사회 분야에서 점점 더 널리 사용되고 있습니다. 인공 신경망(ANN), 정보 기술, 무선 통신은 모두 기존 치료법의 단점을 극복할 수 있는 잠재력을 가진 스마트 약물 전달 시스템 개발에 중요한 역할을 합니다. 무선 연결 덕분에 규제 약물 유통 장치는 더욱 다양한 기능을 제공할 수 있게 되었습니다.
이 보고서에 대한 자세한 내용은 샘플을 요청하십시오.
세분화 분석
전 세계 경구 점막 투여 약물 시장은 제품 유형, 적응증, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
오피오이드 의존증 부문은 예측 기간 동안 경구 점막 투여 약물 시장 점유율의 대부분을 차지할 것으로 예상됩니다.
오피오이드 의존증 적응증은 전체 경구 점막 투여 약물 시장의 약 39.6%를 차지합니다. 오피오이드 과다복용 사례의 증가가 해당 부문의 성장을 견인하고 있습니다. 예를 들어, 세계보건기구(WHO)에 따르면 2021년 전 세계적으로 약물 남용으로 인해 약 50만 명이 사망했습니다. 이 중 70% 이상이 오피오이드와 관련되어 있으며, 약물 과다복용으로 인한 사망의 30% 이상을 차지합니다.
또한, 캐나다와 미국에서 오피오이드 처방은 용납할 수 없는 높은 사망률, 처방 오피오이드 남용, 그리고 영향을 받는 지역사회에 대한 막대한 책임을 초래하고 있습니다.
지역 분석
유럽은 예측 기간 동안 전 세계 경구 점막 투여 약물 시장에서 두 번째로 큰 점유율을 차지할 것으로 예상됩니다.

유럽 지역은 전 세계 경구 점막 투여 약물 시장에서 약 29%의 점유율을 차지하며 두 번째로 큰 시장 점유율을 보이고 있습니다. 유럽 지역 시장의 성장은 통증 관리 수요 증가와 활발한 지역 시장 참여자들에 의해 주도되고 있습니다.

예를 들어, 현재 표준 치료법으로 환자의 문제를 해결하고 삶의 질을 향상시키는 혁신적인 제품을 개발하는 제약 회사인 아퀘스티브 테라퓨틱스(Aquestive Therapeutics, Inc.)는 2022년 9월 파마노비아(Pharmanovia)와 리베르반트(Libervant, 디아제팜) 구강 필름에 대한 라이선스 및 공급 계약을 체결했다고 발표했습니다. 이 계약을 통해 파마노비아는 유럽 연합, 영국 및 기타 국가에서 리베르반트(Libervant, 디아제팜) 구강 필름을 판매할 수 있게 되었습니다.
경쟁 환경
시장의 주요 글로벌 업체로는 화이자(Pfizer Inc.), 짐 래버러토리스(ZIM Laboratories Limited), 아퀘스티브 테라퓨틱스(Aquestive Therapeutics, Inc.), 인텔젠엑스(IntelGenx Corp), 인디비어(Indivior PLC), C.L.팜(C.L.Pharm Co., Ltd.), 서울약품, 실파테라퓨틱스(Shilpa Therapeutics), 수노비온 파마슈티컬스(Sunovion Pharmaceuticals, Inc.), 큐어 파마슈티컬(CURE Pharmaceutical) 등이 있습니다.
보고서 구매 이유
제품, 적용 분야 및 지역별 글로벌 경구 점막 투여 약물 시장 세분화를 시각화하고 주요 사업 자산 및 업체를 파악하기 위함입니다.

트렌드 분석 및 공동 개발을 통해 상업적 기회를 파악하세요.
모든 세그먼트를 포함한 경구 점막 투여 약물 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트가 제공됩니다.
PDF 보고서는 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석 결과를 담고 있습니다.
주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료가 엑셀 파일로 제공됩니다.
글로벌 경구 점막 투여 약물 시장 보고서는 약 53개의 표, 54개의 그림, 그리고 195페이지 분량으로 구성됩니다.
주요 고객 (2023년 기준)
제조업체/구매자
산업 투자자/투자은행가
연구 전문가
신흥 기업

보고서 요약(영어 원문)

Market Overview
The global oral transmucosal drugs market reached US$ 15,005.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 24,441.4 million by 2030. The oral transmucosal drugs market is expected to exhibit a CAGR of 6.4% during the forecast period (2023-2030).
Globally, chronic or non-communicable diseases are on the rise and are responsible for 73% of all fatalities. Non-communicable illnesses are to blame for 44% of lost disability-adjusted life years and 53% of all fatalities in India. More than a sixth of the world's people reside in India, which has been experiencing significant socio-economic development and an epidemiological trend towards chronic non-communicable diseases led to the rise in the oral transmucosal drugs market growth.
The Coronavirus disease 2019 (COVID-19) pandemic has led to a surge in the need for alternative routes of administration of drugs for end-of-life and palliative care, particularly in community settings. Transmucosal routes include intranasal, buccal, sublingual and rectal. They are non-invasive routes for systemic drug delivery with the possibility of self-administration, or administration by family caregivers. The factors such as growing cases of autoimmune disorders, technological advancements, and oral drugs market developments are boosting the global oral transmucosal drugs market growth.
Market Dynamics
Increase in the incidence of autoimmune disorders and cancer to boost the market growth
For instance, each year, the American Cancer Society estimates the number of new cancer cases and deaths in the U.S., and compiles the most recent data on population-based cancer occurrence and outcomes. In 2022, 1,918,030 new cancer cases and 609,360 cancer deaths were projected to occur in the U.S., including approximately 350 deaths per day from lung cancer, the leading cause of cancer. Thus, the prevelance of cancer boost the market growth.
Technical challenges of transmucosal drug
Transmucosal drug delivery is preferable to oral and parenteral forms of administration since it is non-invasive and enables self-administration or administration by trained carers. Understanding the mechanism of mucosal drug absorption is crucial in order to find medications that are right for transmucosal administration. The intranasal, oral, and rectal mucosa each have particular morphological and physiological traits, but they also have several things in common.
COVID-19 Impact Analysis
Due to supply chain disruption, a government-imposed lockdown, manpower shortages, and limitations on manufacturing activities, the COVID-19 pandemic had a short-term detrimental effect on the market for oral transmucosal medications. Oral transmucosal medication producers, on the other hand, are profiting from coronavirus outbreaks by providing reduced first-pass metabolism with a quick onset of action. These qualities make oral transmucosal medications useful for palliative care and end-of-life care to provide quick symptom alleviation. Since some patients' health has a tendency to rapidly decline in some circumstances, it was essential during the COVID-19 pandemic.
Russia-Ukraine Conflict Analysis
The Russia-Ukraine is estimated to have a minimal impact on the global oral transmucosal drugs market, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is anticipated to have little influence over the global oral transmucosal drugs market over the forecast period.
Artificial Intelligence Impact Analysis
Artificial intelligence (AI) has become more prevalent in a number of societal fields, most notably the pharmaceutical industry. Artificial neural networks (ANNs), information technology, and wireless communication all play a role in the development of smart medication delivery systems that have the potential to overcome the drawbacks of traditional therapeutic approaches. Devices for regulated drug distribution are more versatile, thanks to wireless connections.
For more details on this report - Request for Sample
Segment Analysis
The global oral transmucosal drugs market is segmented based on product type, indication, route of administartion, distribution channel, and region.
The opioid dependence segment is estimated to hold a majority of the oral transmucosal drugs market share during the forecast period.
The opioid dependence indication holds about 39.6% of the total oral transmucosal drugs market. The growing cases of opioid overdose is driving the segment growth. For instance, according to the World Health Organization 2021, globally about 0.5 million deaths are caused because of drug abuse. Over 70% of these deaths are associated with opioids, accounting for over 30% of those drug overdose deaths.
Moreover, prescribing of opioids in the Canada and U.S. has caused high rates of unacceptable death rates, prescription opioid abuse, and an immense obligation to the affected communities.
Geographical Analysis
Europe is estimated to hold the second-largest share of the global oral transmucosal drugs market during the forecast period.
The Europe region holds the second largest share of the global oral transmucosal drugs market accounting for approximately 29%. The market in the Europe region is being driven by the rising demand for pain management and active regional market participants.
For instance, Aquestive Therapeutics, Inc., a pharmaceutical company that develops drugs to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced in September 2022 that it entered a license and supply agreement for Libervant (diazepam) Buccal Film with Pharmanovia. This agreement will allow Pharmanovia to market Libervant (diazepam) Buccal Film in the European Union, the UK, and other countries.
Competitive Landscape
The major global players in the market include Pfizer Inc., ZIM Laboratories Limited, Aquestive Therapeutics, Inc, IntelGenx Corp, Indivior PLC, C.L.Pharm Co., Ltd, Seoul Pharmaceuticals, Shilpa Therapeutics, Sunovion Pharmaceuticals, Inc, and CURE Pharmaceutical, among others.
Why Purchase the Report?
To visualize the global oral transmucosal drugs market segmentation based on product, application, and region,as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of oral transmucosal drugs market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.
The global oral transmucosal drugs market report would provide approximately 53 tables, 54figures, and 195 Pages.
Target Audience 2023
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Indication
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increase in incidence of autoimmune disorders, respiratory problems, and cancer to boost the market growth
4.1.1.2. The increase in medication and pharmacological therapy usage
4.1.2. Restraints
4.1.2.1. Regulatory challenges for transmucosal drug
4.1.3. Opportunity
4.1.3.1. Increasing number of research and developments activities
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Before COVID-19 Scenario
6.1.2. Present COVID-19 Scenario
6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Global Recession Analysis
9. Artificial Intelligence Impact Analysis
10. By Product Type
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.1.2. Market Attractiveness Index, By Product Type
10.2. Tablets
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Films
10.4. Liquids & Spray
10.5. Others
11. By Indication
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.1.2. Market Attractiveness Index, By Indication
11.2. Opioid Dependence *
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Neurological Disorders
11.4. Erectile Dysfunction
11.5. Nausea and Vomiting
11.6. Others
12. By Route of Administration
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.1.2. Market Attractiveness Index, By Route of Administration
12.2. Sublingual Mucosa *
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Buccal Mucosa
12.4. Others
13. By Distribution Channel
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.1.2. Market Attractiveness Index, By Distribution Channel
13.2. Retail Pharmacies*
13.2.1. Introduction
13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Hospital Pharmacies
13.4. Online Pharmacies
14. By Region
14.1. Introduction
14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
14.1.2. Market Attractiveness Index, By Region
14.2. North America
14.2.1. Introduction
14.2.2. Key Region-Specific Dynamics
14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.2.7.1. The U.S.
14.2.7.2. Canada
14.2.7.3. Mexico
14.3. Europe
14.3.1. Introduction
14.3.2. Key Region-Specific Dynamics
14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.3.7.1. Germany
14.3.7.2. The U.K.
14.3.7.3. France
14.3.7.4. Italy
14.3.7.5. Spain
14.3.7.6. Rest of Europe
14.4. South America
14.4.1. Introduction
14.4.2. Key Region-Specific Dynamics
14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.4.7.1. Brazil
14.4.7.2. Argentina
14.4.7.3. Rest of South America
14.5. Asia-Pacific
14.5.1. Introduction
14.5.2. Key Region-Specific Dynamics
14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.5.7.1. China
14.5.7.2. India
14.5.7.3. Japan
14.5.7.4. Australia
14.5.7.5. Rest of Asia-Pacific
14.6. Middle East and Africa
14.6.1. Introduction
14.6.2. Key Region-Specific Dynamics
14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
15. Competitive Landscape
15.1. Competitive Scenario
15.2. Market Share Analysis
15.3. Mergers and Acquisitions Analysis
16. Company Profiles
16.1. Pfizer Inc.*
16.1.1. Company Overview
16.1.2. Product Portfolio and Description
16.1.3. Financial Overview
16.1.4. Key Developments
16.2. ZIM Laboratories Limited
16.3. Aquestive Therapeutics, Inc
16.4. IntelGenx Corp
16.5. Indivior PLC
16.6. C.L.Pharm Co., Ltd
16.7. Seoul Pharmaceuticals
16.8. Shilpa Therapeutics
16.9. Sunovion Pharmaceuticals, Inc
16.10. CURE Pharmaceutical. (LIST NOT EXHAUSTIVE)
17. Appendix
17.1. About Us and Services
17.2. Contact Us

언급된 주요 기업들

Pfizer Inc., 4. Key Developments, ZIM Laboratories Limited, Aquestive Therapeutics, Inc, IntelGenx Corp, Indivior PLC, C.L.Pharm Co., Ltd, Seoul Pharmaceuticals, Shilpa Therapeutics, Sunovion Pharmaceuticals, Inc

표 목록 (Tables)

List of Tables

Table 1Global Oral Transmucosal Drugs Market Value, By Product Type, 2022, 2026 & 2030 ($ Million)

Table 2Global Oral Transmucosal Drugs Market Value, By Indication, 2022, 2026 & 2030 ($ Million)

Table 3Global Oral Transmucosal Drugs Market Value, By Route of Administration, 2022, 2026 & 2030 ($ Million)

Table 4Global Oral Transmucosal Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 ($ Million)

Table 5Global Oral Transmucosal Drugs Market Value, By Region, 2022, 2026 & 2030 ($ Million)

Table 6Global Oral Transmucosal Drugs Market Value, By Product Type, 2022, 2026 & 2030 ($ Million)

Table 7Global Oral Transmucosal Drugs Market Value, By Product Type, 2021-2030 ($ Million)

Table 8Global Oral Transmucosal Drugs Market Value, By Indication, 2022, 2026 & 2030 ($ Million)

Table 9Global Oral Transmucosal Drugs Market Value, By Indication, 2021-2030 ($ Million)

Table 10Global Oral Transmucosal Drugs Market Value, By Route of Administration, 2022, 2026 & 2030 ($ Million)

Table 11Global Oral Transmucosal Drugs Market Value, By Route of Administration, 2021-2030 ($ Million)

Table 12Global Oral Transmucosal Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 ($ Million)

Table 13Global Oral Transmucosal Drugs Market Value, By Distribution Channel, 2021-2030 ($ Million)

Table 14Global Oral Transmucosal Drugs Market Value, By Region, 2022, 2026 & 2030 ($ Million)

Table 15Global Oral Transmucosal Drugs Market Value, By Region, 2021-2030 ($ Million)

Table 16North America Oral Transmucosal Drugs Market Value, By Product Type, 2021-2030 ($ Million)

Table 17North America Oral Transmucosal Drugs Market Value, By Indication, 2021-2030 ($ Million)

Table 18North America Oral Transmucosal Drugs Market Value, By Route of Administration, 2021-2030 ($ Million)

Table 19North America Oral Transmucosal Drugs Market Value, By Distribution Channel, 2021-2030 ($ Million)

Table 20North America Oral Transmucosal Drugs Market Value, By Country, 2021-2030 ($ Million)

Table 21South America Oral Transmucosal Drugs Market Value, By Product Type, 2021-2030 ($ Million)

Table 22South America Oral Transmucosal Drugs Market Value, By Indication, 2021-2030 ($ Million)

Table 23South America Oral Transmucosal Drugs Market Value, By Route of Administration, 2021-2030 ($ Million)

Table 24South America Oral Transmucosal Drugs Market Value, By Distribution Channel, 2021-2030 ($ Million)

Table 25South America Oral Transmucosal Drugs Market Value, By Country, 2021-2030 ($ Million)

Table 26Europe Oral Transmucosal Drugs Market Value, By Product Type, 2021-2030 ($ Million)

Table 27Europe Oral Transmucosal Drugs Market Value, By Indication, 2021-2030 ($ Million)

Table 28Europe Oral Transmucosal Drugs Market Value, By Route of Administration, 2021-2030 ($ Million)

Table 29Europe Oral Transmucosal Drugs Market Value, By Distribution Channel, 2021-2030 ($ Million)

Table 30Europe Oral Transmucosal Drugs Market Value, By Country, 2021-2030 ($ Million)

Table 31Asia-Pacific Oral Transmucosal Drugs Market Value, By Product Type, 2021-2030 ($ Million)

Table 32Asia-Pacific Oral Transmucosal Drugs Market Value, By Indication, 2021-2030 ($ Million)

Table 33Asia-Pacific Oral Transmucosal Drugs Market Value, By Route of Administration, 2021-2030 ($ Million)

Table 34Asia-Pacific Oral Transmucosal Drugs Market Value, By Distribution Channel, 2021-2030 ($ Million)

Table 35Asia-Pacific Oral Transmucosal Drugs Market Value, By Country, 2021-2030 ($ Million)

Table 36Middle East & Africa Oral Transmucosal Drugs Market Value, By Product Type, 2021-2030 ($ Million)

Table 37Middle East & Africa Oral Transmucosal Drugs Market Value, By Indication, 2021-2030 ($ Million)

Table 38Middle East & Africa Oral Transmucosal Drugs Market Value, By Route of Administration, 2021-2030 ($ Million)

Table 39Middle East & Africa Oral Transmucosal Drugs Market Value, By Distribution Channel, 2021-2030 ($ Million)

Table 40Pfizer Inc.: Overview

Table 41Pfizer Inc.: Product Portfolio

Table 42Pfizer Inc.: Key Developments

Table 43ZIM Laboratories Limited: Overview

Table 44ZIM Laboratories Limited: Product Portfolio

Table 45ZIM Laboratories Limited: Key Developments

Table 46Aquestive Therapeutics, Inc: Overview

Table 47Aquestive Therapeutics, Inc: Product Portfolio

Table 48Aquestive Therapeutics, Inc: Key Developments

Table 49IntelGenx Corp: Overview

Table 50IntelGenx Corp: Product Portfolio

Table 51IntelGenx Corp: Key Developments

Table 52Indivior PLC: Overview

Table 53Indivior PLC: Product Portfolio

Table 54Indivior PLC: Key Developments

Table 55C.L.Pharm Co., Ltd: Overview

Table 56C.L.Pharm Co., Ltd: Product Portfolio

Table 57C.L.Pharm Co., Ltd: Key Developments

Table 58Seoul Pharmaceuticals: Overview

Table 59Seoul Pharmaceuticals: Product Portfolio

Table 60Seoul Pharmaceuticals: Key Developments

Table 61Shilpa Therapeutics: Overview

Table 62Shilpa Therapeutics: Product Portfolio

Table 63Shilpa Therapeutics: Key Developments

Table 64Sunovion Pharmaceuticals, Inc: Overview

Table 65Sunovion Pharmaceuticals, Inc: Product Portfolio

Table 66Sunovion Pharmaceuticals, Inc: Key Developments

Table 67CURE Pharmaceutical: Overview

Table 68CURE Pharmaceutical: Product Portfolio

Table 69CURE Pharmaceutical: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1Global Oral Transmucosal Drugs Market Share, By Product Type, 2022 & 2030 (%)

Figure 2Global Oral Transmucosal Drugs Market Share, By Indication, 2022 & 2030 (%)

Figure 3Global Oral Transmucosal Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 4Global Oral Transmucosal Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 5Global Oral Transmucosal Drugs Market Share, By Region, 2022 & 2030 (%)

Figure 6Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)

Figure 7Global Oral Transmucosal Drugs Market Y-o-Y Growth, By Product Type, 2021-2030 (%)

Figure 8Tablets: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)

Figure 9Films: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)

Figure 10Liquids & Spray: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)

Figure 11Others: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)

Figure 12Global Oral Transmucosal Drugs Market Y-o-Y Growth, By Indication, 2021-2030 (%)

Figure 13Opioid Dependence: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)

Figure 14Neurological Disorders: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)

Figure 15Erectile Dysfunction: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)

Figure 16Nausea and Vomiting: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)

Figure 17Others: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)

Figure 18Global Oral Transmucosal Drugs Market Y-o-Y Growth, By Route of Administration, 2021-2030 (%)

Figure 19Sublingual Mucosa: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)

Figure 20Buccal Mucosa: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)

Figure 21Others: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)

Figure 22Global Oral Transmucosal Drugs Market Y-o-Y Growth, By Distribution Channel, 2021-2030 (%)

Figure 23Retail Pharmacies: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)

Figure 24Hospital Pharmacies: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)

Figure 25Online Pharmacies: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)

Figure 26Global Oral Transmucosal Drugs Market Y-o-Y Growth, By Region, 2021-2030 (%)

Figure 27North America Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)

Figure 28North America Oral Transmucosal Drugs Market Share, By Product Type, 2022 & 2030 (%)

Figure 29North America Oral Transmucosal Drugs Market Share, By Indication, 2022 & 2030 (%)

Figure 30North America Oral Transmucosal Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 31North America Oral Transmucosal Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 32North America Oral Transmucosal Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 33South America Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)

Figure 34South America Oral Transmucosal Drugs Market Share, By Product Type, 2022 & 2030 (%)

Figure 35South America Oral Transmucosal Drugs Market Share, By Indication, 2022 & 2030 (%)

Figure 36South America Oral Transmucosal Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 37South America Oral Transmucosal Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 38South America Oral Transmucosal Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 39Europe Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)

Figure 40Europe Oral Transmucosal Drugs Market Share, By Product Type, 2022 & 2030 (%)

Figure 41Europe Oral Transmucosal Drugs Market Share, By Indication, 2022 & 2030 (%)

Figure 42Europe Oral Transmucosal Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 43Europe Oral Transmucosal Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 44Europe Oral Transmucosal Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 45Asia-Pacific Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)

Figure 46Asia-Pacific Oral Transmucosal Drugs Market Share, By Product Type, 2022 & 2030 (%)

Figure 47Asia-Pacific Oral Transmucosal Drugs Market Share, By Indication, 2022 & 2030 (%)

Figure 48Asia-Pacific Oral Transmucosal Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 49Asia-Pacific Oral Transmucosal Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 50Asia-Pacific Oral Transmucosal Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 51Middle East & Africa Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)

Figure 52Middle East & Africa Oral Transmucosal Drugs Market Share, By Product Type, 2022 & 2030 (%)

Figure 53Middle East & Africa Oral Transmucosal Drugs Market Share, By Indication, 2022 & 2030 (%)

Figure 54Middle East & Africa Oral Transmucosal Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 55Middle East & Africa Oral Transmucosal Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 56Pfizer Inc.: Financials

Figure 57ZIM Laboratories Limited: Financials

Figure 58Aquestive Therapeutics, Inc: Financials

Figure 59IntelGenx Corp: Financials

Figure 60Indivior PLC: Financials

Figure 61C.L.Pharm Co., Ltd: Financials

Figure 62Seoul Pharmaceuticals: Financials

Figure 63Shilpa Therapeutics: Financials

Figure 64Sunovion Pharmaceuticals, Inc: Financials

Figure 65CURE Pharmaceutical: Financials